Saxagliptin
CAS 361442-04-8
Overview
Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic of the dipeptidyl peptidase-4 inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug
Anant Labs manufacture and furnish high quality Saxagliptin impurities for global markets. Our Saxagliptin EP Impurities are used by API manufacturers and fully integrated pharmaceutical companies worldwide.
